Transplant
8 videos · last 6 months shuffled daily, then older videos newest first
▶
6:20 MONVISO: Etentamig Efficacy by Prior BCMA Therapy
Saurabh Chhabra, MBBS, MS, of Mayo Clinic Arizona describes how efficacy of etentamig, a BCMA x CD3 bispecific, varied by prior BCMA-targeting therapy in the phase 1b MONVISO study presented at ASCO 2026, for Blood Cancers Today.
▶
1:26 Iberdomide FDA Approval and the Next CELMoDs in Myeloma
Sagar Lonial, MD, discusses the FDA approval of iberdomide for multiple myeloma and the CELMoD trials to watch next, including mezigdomide in the phase 3 SUCCESSOR-2 trial, at the 2026 International Myeloma Society meeting, for Targeted Oncology.
▶
56:34 Luxa's RPE Stem Cell Therapy: Phase 1 Trial in AMD
Dr. Jeffrey Stern, co-founder of the Neural Stem Cell Institute and co-CEO of Luxa Biotechnology, discusses its stem cell-derived RPE therapy, early results from a first-in-human Phase 1 trial in late-stage AMD and plans to include inherited retinal disease.
▶
6:53 IBEX Study: Iberdomide Plus Daratumumab Myeloma Maintenance
Jeffrey Zonder, MD, of Karmanos Cancer Institute discusses first results from the IBEX study of iberdomide plus subcutaneous daratumumab as maintenance after stem cell transplant, including side effects and MRD responses, at IMS 2026.
▶
2:12 Freedom from Immunosuppression for Kidney Transplant Patients at Mayo
Mayo Clinic looks at an ongoing living donor kidney transplant clinical trial.
▶
10:21 KOAR Study Highlights Promise of dd-cfDNA in Kidney Transplant
Nephrology Times on the KOAR study, published in the American Journal of Transplantation — the largest prospective study of donor-derived cell-free DNA in kidney transplant monitoring.
▶
3:27 Diabetes Research Institute on One Year Insulin-Free After an Islet Cell Transplant
Marlaina Goedel took part in a Diabetes Research Institute trial testing pancreatic islet cell transplants alongside anti-CD40 ligand, a newer anti-rejection drug. A year on she is living without insulin.
▶
2:49 Faecal Microbiota Transplant Trial in Graft-versus-Host Disease
QIMR Berghofer describes a clinical trial led by Dr Andrea Henden at the Royal Brisbane and Women's Hospital testing faecal microbiota transplant in blood cancer survivors with severe graft-versus-host disease after bone marrow transplant.